[Fundamental and clinical studies of aztreonam in the field of pediatric]. 1985

S Nakazawa, and H Sato, and A Narita, and K Matsumoto, and H Suzuki, and S Nakazawa, and H Chikaoka, and M Kamigaki, and R Koido, and Y Nakada

The fundamental and clinical studies of aztreonam (AZT) were performed. The results were as follows: The MICs of AZT for E. coli and Salmonella sp. which were recently isolated in the pediatric field were less than 0.78 micrograms/ml. AZT also was effective against ABPC/PIPC-resistant bacteria. The MIC of AZT for V. parahaemolyticus was less than 1.56 micrograms/ml. The peak serum levels of AZT which were occurred just after the 1 hour drip infusion of 10-30 mg/kg were 60.5-136.8 micrograms/ml, and at 6 hours after infusion the serum levels were 1.3-6.1 micrograms/ml; therefore, the dose response was proved. The mean half-lives (T 1/2) were between 1.21 and 1.36 hours. The excretion rates in urine up to 6 hours after intravenous drip infusion were between 32.7 and 77.5%. The ratio of the cerebrospinal fluid concentration to serum in the child with purulent meningitis was 3.5% at 1 hour after the intravenous injection at the dose of 69 mg/kg, and the ratios of the subdural fluid levels to serum were 31.3-37.5%. The levels of AZT into the feces by the multiple dosage were 0-840 micrograms/g. Twenty-five pediatric patients with acute infections had been treated by intravenous injection or drip infusion at the doses of 49-120 mg/kg/day (almost 50-100 mg/kg/day) for 4 to 13 days. The efficacy rate of excellent + good was 84% and that of excellent + good + fair was 96%. The efficacy rate of excellent + good was 100% in all cases with upper/lower respiratory tract infection, bronchopneumonia, and acute urinary tract infection caused by Gram-negative rods. The clinical efficacy was observed in all cases with acute bacterial enteritis. Although AZT was clinically effective against Salmonella enteritis, bacteriological efficacy on the causative organisms was not observed in some cases. Although AZT was bacteriologically effective in 1 patient with typhoid, it did not alleviated fever. AZT showed activity to 9 strains isolated from the culture of throat swab, urine and feces. No side effects were clinically observed in all cases, while slight elevations of laboratory findings were observed in 4 cases.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D001398 Aztreonam A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms. Az-threonam,Azactam,Azthreonam,SQ-26,776,Urobactam,Az threonam,SQ 26,776,SQ26,776

Related Publications

S Nakazawa, and H Sato, and A Narita, and K Matsumoto, and H Suzuki, and S Nakazawa, and H Chikaoka, and M Kamigaki, and R Koido, and Y Nakada
November 1985, The Japanese journal of antibiotics,
S Nakazawa, and H Sato, and A Narita, and K Matsumoto, and H Suzuki, and S Nakazawa, and H Chikaoka, and M Kamigaki, and R Koido, and Y Nakada
November 1985, The Japanese journal of antibiotics,
S Nakazawa, and H Sato, and A Narita, and K Matsumoto, and H Suzuki, and S Nakazawa, and H Chikaoka, and M Kamigaki, and R Koido, and Y Nakada
December 1985, The Japanese journal of antibiotics,
S Nakazawa, and H Sato, and A Narita, and K Matsumoto, and H Suzuki, and S Nakazawa, and H Chikaoka, and M Kamigaki, and R Koido, and Y Nakada
November 1985, The Japanese journal of antibiotics,
S Nakazawa, and H Sato, and A Narita, and K Matsumoto, and H Suzuki, and S Nakazawa, and H Chikaoka, and M Kamigaki, and R Koido, and Y Nakada
December 1985, The Japanese journal of antibiotics,
S Nakazawa, and H Sato, and A Narita, and K Matsumoto, and H Suzuki, and S Nakazawa, and H Chikaoka, and M Kamigaki, and R Koido, and Y Nakada
December 1985, The Japanese journal of antibiotics,
S Nakazawa, and H Sato, and A Narita, and K Matsumoto, and H Suzuki, and S Nakazawa, and H Chikaoka, and M Kamigaki, and R Koido, and Y Nakada
December 1985, The Japanese journal of antibiotics,
S Nakazawa, and H Sato, and A Narita, and K Matsumoto, and H Suzuki, and S Nakazawa, and H Chikaoka, and M Kamigaki, and R Koido, and Y Nakada
December 1985, The Japanese journal of antibiotics,
S Nakazawa, and H Sato, and A Narita, and K Matsumoto, and H Suzuki, and S Nakazawa, and H Chikaoka, and M Kamigaki, and R Koido, and Y Nakada
December 1985, The Japanese journal of antibiotics,
S Nakazawa, and H Sato, and A Narita, and K Matsumoto, and H Suzuki, and S Nakazawa, and H Chikaoka, and M Kamigaki, and R Koido, and Y Nakada
December 1985, The Japanese journal of antibiotics,
Copied contents to your clipboard!